Zofran Birth Defect Lawsuit Plaintiff Alleges GSK Experimented With Off-Label Use

November 16, 2015 – – ZofranLegal.com reports on recent allegations by a mother in federal court who has filed a birth defect lawsuit against GlaxoSmithKline and their anti-nausea drug zofran. The woman alleged that by marketing the drug for use by expectant mothers, a use which was not FDA approved or safety tested, the pharmaceutical giant was “experimenting with the lives of unsuspecting mothers-to-be and their babies.” Additionally, she notes that this was done with a “profit maximization” slogan for physicians.

This is not the first time that GlaxoSmithKline has been under the microscope for marketing their drugs for “off-label” uses. The manufacturer was sued in 2012 by the United States Department of Justice for this reason. The drugs discussed in that suit included Zofran. GSK settled this lawsuit in 2012 and agreed to pay fines totalling $3 billion.

In this particular lawsuit, the plaintiff goes on to note that GSK was also ordered by the U.S. Food and Drug Administration in 1999 to “immediately cease distribution” of marketing advertisements that “promote Zofran in a manner that is false or misleading because it lacks fair balance.” Despite these warnings the manufacturing company, according to allegations, launched yet another “fraudulent marketing campaign” which attained Zofran and GSK over $1 billion in annual sales.

The woman goes on to note her personal experience with Zofran, indicating that after using the drug to treat nausea while pregnant, she had given birth to a baby with birth defects. Specifically, her infant daughter was born with congenital band syndrome and teratologic clubfoot. Her allegations are similar to those of many, which is why zofran birth defect lawsuits have now been consolidated for form multidistrict litigation 2657 in Boston, Massachusetts. This process is designed to help litigation run more smoothly and efficiently, avoid duplicate discovery and conserve the resources of those involved.

Because there are more than 6 million pregnancies annually across the nation, and an estimated 70-80% of those pregnancies involving nausea, it is anticipated that more lawsuits will join those currently in the MDL as they await trial. The attorneys at Monheit Law are working to do their part to ensure that anyone who was prescribed Zofran while pregnant, and who later gave birth to a child with defects, has the opportunity to explore their full legal rights. Defects most commonly alleged are cleft lip and palate, atrial septal defect and ventricular septal defect, transposition of the greater vessels, tetralogy of fallot, clubfoot, and kidney defects. Those who have children that have been diagnosed with these may be entitled to compensation. The attorneys at Monheit Law are offering free consultations to those involved.

For additional information on zofran birth defect lawsuits, or to ask questions, please contact Michael Monheit, Esq. by calling 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005473